C9081 Idecabtagene car pos t

Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• Medicare coverage: Special coverage instructions apply
• Status: terminated 20211231